TIGIT and cancer: Tumor Tregs, compared to the liver and blood, showed upregulation of markers of Treg activation and cancer-associated immune suppression, such as IL2RA, IL1R2, FOXP3, TIGIT, CTLA4, ENTPD1, CXCL13, CXCR4, and RGS1 (Supplementary Fig. S3C, Supplementary Table S5).